CA3226539A1 - Peptide inhibitors of interleukin-23 receptor - Google Patents

Peptide inhibitors of interleukin-23 receptor Download PDF

Info

Publication number
CA3226539A1
CA3226539A1 CA3226539A CA3226539A CA3226539A1 CA 3226539 A1 CA3226539 A1 CA 3226539A1 CA 3226539 A CA3226539 A CA 3226539A CA 3226539 A CA3226539 A CA 3226539A CA 3226539 A1 CA3226539 A1 CA 3226539A1
Authority
CA
Canada
Prior art keywords
pen
aef
thp
ccc
conh2
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
CA3226539A
Other languages
English (en)
French (fr)
Inventor
Chengzao Sun
Santhosh Neelamkavil
Raymond J. Patch
Stephanie A. Barros
Sandeep Somani
Charles HENDRICK
Jing Zhang
Elisabetta Bianchi
Roberto COSTANTE
Raffaele Ingenito
Danila Branca
Ashok Bhandari
Brian Frederick
James Daniel
Tran Trung Tran
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Janssen Biotech Inc
Protagonist Therapeutics Inc
Original Assignee
Janssen Biotech Inc
Protagonist Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Janssen Biotech Inc, Protagonist Therapeutics Inc filed Critical Janssen Biotech Inc
Publication of CA3226539A1 publication Critical patent/CA3226539A1/en
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C07K14/54—Interleukins [IL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Rheumatology (AREA)
  • Pain & Pain Management (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Epidemiology (AREA)
CA3226539A 2021-07-14 2022-07-14 Peptide inhibitors of interleukin-23 receptor Pending CA3226539A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163221806P 2021-07-14 2021-07-14
US63/221,806 2021-07-14
PCT/US2022/037221 WO2023288028A2 (en) 2021-07-14 2022-07-14 Peptide inhibitors of interleukin-23 receptor

Publications (1)

Publication Number Publication Date
CA3226539A1 true CA3226539A1 (en) 2023-01-19

Family

ID=84920532

Family Applications (1)

Application Number Title Priority Date Filing Date
CA3226539A Pending CA3226539A1 (en) 2021-07-14 2022-07-14 Peptide inhibitors of interleukin-23 receptor

Country Status (11)

Country Link
US (1) US20240409598A1 (https=)
EP (1) EP4370531A4 (https=)
JP (1) JP2024525780A (https=)
KR (1) KR20240034222A (https=)
CN (1) CN117999274A (https=)
AU (1) AU2022310354A1 (https=)
CA (1) CA3226539A1 (https=)
MX (1) MX2024000762A (https=)
TW (1) TW202332683A (https=)
UY (1) UY39856A (https=)
WO (1) WO2023288028A2 (https=)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP4091624A1 (en) 2013-03-15 2022-11-23 Protagonist Therapeutics, Inc. Hepcidin analogues and uses thereof
HRP20211448T1 (hr) 2014-05-16 2021-12-24 Protagonist Therapeutics, Inc. Alfa4beta7 integrin tioeter peptidni antagonisti
CN107206254B (zh) 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
CA3089868A1 (en) 2018-02-08 2019-08-15 Protagonist Therapeutics, Inc. Conjugated hepcidin mimetics
AU2021209086A1 (en) 2020-01-15 2022-08-04 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7397239B2 (ja) 2020-11-20 2023-12-12 ヤンセン ファーマシューティカ エヌ．ベー． インターロイキン－２３受容体のペプチド阻害剤の組成物
EP4370146A4 (en) 2021-07-14 2025-05-21 Janssen Biotech, Inc. Lipidated peptide inhibitors of the interleukin-23 receptor
EP4652180A2 (en) * 2023-01-16 2025-11-26 Janssen Pharmaceutica NV Peptide inhibitors of interleukin-23 receptor
US20240279281A1 (en) * 2023-01-16 2024-08-22 Janssen Pharmaceutica Nv Peptide Inhibitors of Interleukin-23 Receptor
WO2024155553A1 (en) * 2023-01-16 2024-07-25 Janssen Pharmaceutica Nv Lipidated peptide inhibitors of interleukin-23 receptor
IL322423A (en) * 2023-01-31 2025-09-01 Janssen Pharmaceutica Nv Methods for preparing crystalline peptide inhibitors of the interleukin-23 receptor
CN120826233A (zh) * 2023-03-03 2025-10-21 詹森药业有限公司 用于治疗银屑病的白介素-23受体拮抗剂肽
EP4471048A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
EP4471049A1 (en) 2023-06-01 2024-12-04 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
CN121909205A (zh) 2023-09-08 2026-04-21 赛诺菲 作为选择性il-23受体抑制剂的新型肽
CN121794283A (zh) 2023-09-08 2026-04-03 赛诺菲 作为选择性il-23受体抑制剂的新型肽
WO2026013260A1 (en) 2024-07-12 2026-01-15 Zealand Pharma A/S Peptide inhibitors of interleukin-23 receptor
WO2026026816A1 (zh) * 2024-07-30 2026-02-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂及其用途
WO2026041110A1 (zh) * 2024-08-22 2026-02-26 上海瀚辰星泰医药科技有限公司 一种多肽化合物及其应用
WO2026046292A1 (zh) * 2024-08-28 2026-03-05 西藏海思科制药有限公司 白介素-23受体的肽抑制剂的药物组合物及其制备方法和用途

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US9605027B2 (en) * 2011-06-14 2017-03-28 Medical Diagnostic Laboratories, Llc Polypeptides that bound to IL-23 receptor and inhibit binding of IL-23 and cell signaling thereof
CN107206254B (zh) * 2014-07-17 2021-08-24 领导医疗有限公司 白细胞介素-23受体的口服肽抑制剂以及其治疗炎症性肠病的用途
US10787490B2 (en) * 2015-07-15 2020-09-29 Protaganist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
MX384213B (es) * 2015-07-15 2025-03-14 Protagonist Therapeutics Inc Inhibidores peptidicos del receptor de interleucina 23 y su uso para tratar enfermedades inflamatorias.
WO2018136646A1 (en) * 2017-01-18 2018-07-26 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
WO2020014646A1 (en) * 2018-07-12 2020-01-16 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
JP7534382B2 (ja) * 2019-07-10 2024-08-14 プロタゴニスト セラピューティクス， インコーポレイテッド インターロイキン－２３受容体のペプチド阻害剤及び炎症性疾患を治療するためのその使用
WO2021007433A1 (en) * 2019-07-10 2021-01-14 Protagonist Therapeutics, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases
CA3167751A1 (en) * 2020-01-15 2021-07-22 Janssen Biotech, Inc. Peptide inhibitors of interleukin-23 receptor and their use to treat inflammatory diseases

Also Published As

Publication number Publication date
AU2022310354A1 (en) 2024-02-29
EP4370531A2 (en) 2024-05-22
KR20240034222A (ko) 2024-03-13
JP2024525780A (ja) 2024-07-12
UY39856A (es) 2023-02-28
EP4370531A4 (en) 2025-09-03
WO2023288028A2 (en) 2023-01-19
TW202332683A (zh) 2023-08-16
CN117999274A (zh) 2024-05-07
MX2024000762A (es) 2024-04-18
US20240409598A1 (en) 2024-12-12
WO2023288028A3 (en) 2023-02-23

Similar Documents

Publication Publication Date Title
CA3226539A1 (en) Peptide inhibitors of interleukin-23 receptor
CA3226532A1 (en) Lipidated peptide inhibitors of interleukin-23 receptor
CA3226492A1 (en) Bicyclic peptide inhibitors of interleukin-23 receptor
CN110709414A (zh) Gip受体活化肽
DK2697246T3 (en) SELECTIVE CYSTEIN PROTEASE INHIBITORS AND USES THEREOF
KR20160067840A (ko) 펩티드-올리고우레아 키메라 화합물 및 이의 사용 방법
JP2025120320A (ja) Ｖｉｐｒ２アンタゴニストペプチド
KR20260007614A (ko) 인터루킨-23 수용체의 펩타이드 억제제의 제조 및 이의 용도
KR20170005495A (ko) 돌라프로인-돌라이소류인 펩타이드의 유도체
JP6118892B2 (ja) デュオカルマイシン類縁体の環式プロドラッグ
TW201919682A (zh) 活化Ｎｒｆ２路徑的新穎化合物
AU2021236951A1 (en) Oral GLP receptor agonists
US11879021B2 (en) Cyclic peptides and uses thereof
WO2002102833A1 (fr) Nouveaux derives d'endomorphine
WO2013129660A1 (ja) オキシトシン受容体作動および／またはバソプレッシン受容体拮抗剤
HK40111925A (zh) 白介素-23受体的脂化肽抑制剂
WO2023088236A1 (zh) Mt1-mmp的双环肽配体及其缀合物
SA110310791B1 (ar) مساعدات glp-2 ببتيدية

Legal Events

Date Code Title Description
MFA Maintenance fee for application paid

Free format text: FEE DESCRIPTION TEXT: MF (APPLICATION, 3RD ANNIV.) - STANDARD

Year of fee payment: 3

U00 Fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U00-U101 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE REQUEST RECEIVED

Effective date: 20250603

U11 Full renewal or maintenance fee paid

Free format text: ST27 STATUS EVENT CODE: A-1-1-U10-U11-U102 (AS PROVIDED BY THE NATIONAL OFFICE); EVENT TEXT: MAINTENANCE FEE PAYMENT PAID IN FULL

Effective date: 20250603